[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336070-105":59,"doc-detail-336070-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","review-targeted-combination-of-polyadp-ribose-polymerase-inhibitors-and-immune-checkpoint-inhibitors-lacking-evidence-of-benefit-focus-in-ovarian-cancer","Review - Targeted Combination of Poly(ADP-ribose) Polymerase Inhibitors and Immune Checkpoint Inhibitors Lacking Evidence of Benefit - Focus in Ovarian Cancer","","The emergence of targeted therapeutics in ovarian cancer, particularly poly (ADP-ribose) polymerase inhibitors (PARPi’s), has expanded options for managing frontline and recurrent disease. PARPi’s have shown clinical benefits in BRCA mutant and/or homologous recombination deficient (HRD) ovarian cancer, while evidence for BRCA wild-type and homologous recombination proficient (HRP) tumors remains limited. Immune checkpoint inhibitors (ICIs) have also shown underwhelming results in ovarian cancer, motivating the search for reliable immune-response biomarkers. This review evaluates evidence for PARPi plus ICIs combinations in ovarian cancer, which is still lacking.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/review-targeted-combination-of-polyadp-ribose-polymerase-inhibitors-and-immune-checkpoint-inhibitors-lacking-evidence-of-benefit-focus-in-ovarian-cancer/336070/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/review-targeted-combination-of-polyadp-ribose-polymerase-inhibitors-and-immune-checkpoint-inhibitors-lacking-evidence-of-benefit-focus-in-ovarian-cancer/336070.png","ImageObject",300,407,{"name":92,"@type":93},"Lucas Martin","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are PARP inhibitors of interest in ovarian cancer?","Question",{"text":112,"@type":113},"PARP inhibition targets DNA repair pathways. PARPi’s are particularly beneficial in BRCA-mutant and/or homologous recombination deficient (HRD) ovarian cancer, where DNA repair is already impaired.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What limitation motivates combination therapy with PARP inhibitors and immune checkpoint inhibitors?",{"text":117,"@type":113},"Immune checkpoint inhibitors have shown underwhelming clinical benefits in ovarian cancer, and responses have been limited for BRCA wild-type, homologous recombination proficient (HRP) cancers. This drives attempts to improve outcomes using combination approaches and related biomarker guidance.",{"name":119,"@type":110,"acceptedAnswer":120},"Which biomarkers are mentioned as potentially relevant for ICI effectiveness?",{"text":121,"@type":113},"The text highlights programmed death ligand-1 (PD-L1), tumor mutational burden (TMB), tumor-infiltrating lymphocytes (TILs), and tumor microenvironment (TME) components as biomarkers used in other cancers to enhance ICI activity.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},336070,1790642142,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},8796095360427,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Review  \nTargeted Combination of Poly(ADP-ribose) Polymerase Inhibitors and Immune Checkpoint Inhibitors Lacking Evidence of Benefit: Focus in Ovarian Cancer  \nMorgan Bailey 1, Susan Morand 1, Rachel Royfman 1, Leslie Lin 1, Aditi Singh 1, Laura Stanbery 2, Adam Walter 2,3, Danae Hamouda 1 and John Nemunaitis 2, *  \nCitation: Bailey, M.; Morand, S.; Royfman, R.; Lin, L.; Singh, A.;  \nStanbery, L.; Walter, A.; Hamouda, D.; Nemunaitis, J. Targeted Combination of Poly(ADP-ribose) Polymerase Inhibitors and Immune Checkpoint Inhibitors Lacking Evidence of Benefit:  \nFocus in Ovarian Cancer. Int. J. Mol. Sci. 2024, 25, 3173. [https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.3390/ijms25063173](10.3390/ijms25063173)  \nAcademic Editor: Antonella Tomassetti  \nReceived: 12 December 2023  \nRevised: 1 March 2024  \nAccepted: 5 March 2024  \nPublished: 9 March 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Medicine, University of Toledo, Toledo, OH 43614, USA  \n2 Gradalis, Inc., Dallas, TX 75006, USA; [lnejedlik@gradalisinc.com](lnejedlik@gradalisinc.com)  \n3 Department of Gynecologic Oncology, Promedica, Toledo, OH 43614, USA  \n* [Correspondence: jnemunaitis@gradalisinc.com](Correspondence: jnemunaitis@gradalisinc.com)  \nAbstract: The emergence of targeted therapeutics in ovarian cancer, particularly poly (ADP-ribose) polymerase inhibitors (PARPi’s), has created additional opportunities for patients seeking frontline and recurrent disease management options. In particular, PARPi’s have shown clinical benefits in BRCA mutant and/or homologous recombination deficient (HRD) ovarian cancer. Until recently, response was thought to be limited in BRCA wild-type, homologous recombination proficient (HRP) cancers. Therefore, attempts have been made at combination therapy involving PARPi to improve patient outcomes. Additionally, immune checkpoint inhibitors (ICIs) have demonstrated underwhelming results involving ovarian cancer. Many are searching for reliable biomarkers of immune response to increase efficacy of ICI therapy involving ovarian cancer. In this review, we examine the evidence supporting the combination of PARPi and ICIs in ovarian cancer, which is still lacking.  \nKeywords: ovarian cancer; PARP inhibitor; immunotherapy; BRCA; homologous recombination; HRD; HRP; checkpoint inhibitor  \n1. Introduction  \nThe successful application of molecular-based and pathway-directed technology has shifted the focus of anticancer drug development toward precision medicine, where novel therapeutics have met success in the clinical sphere [1] . A molecular approach that has gained traction in gynecologic oncology is the inhibition of the poly(ADP-ribose) polymerase (PARP) family of proteins, which are centrally involved in DNA repair [2–5] . Early use of these therapeutics was focused on cells with DNA repair deficiency, initially represented by somatic or germline mutations involving BRCA1 and/or BRCA2 genes. In gynecologic oncology, PARPi’s were initially tested in ovarian cancer, which has a 15–30% prevalence of somatic or germline BRCA1/2 mutations [4] . Recently, their application has been expanded to include multiple cancers and has extended beyond BRCA1/2 mutations containing tumors to include a broader range of genetic mutations, involving DNA repair and defects involving homologous repair pathway [4,6], such as BRIP1, RAD51C, RAD51D, ATM, PALB2, CHEK2, etc.  \nImprovements in clinical outcomes have also been found in the field of cancer immunotherapy, particularly with checkpoint inhibitors [7] . In other cancers, anticancer activity of checkpoint inhibitors has also been demonstrated as enhanced via the ex","cbCaisO6P2KWPxGA","https://ap.wps.com/l/cbCaisO6P2KWPxGA","pdf",378769,21,"English","# Abstract\n# Introduction\n## PARP inhibition in ovarian cancer\n## Checkpoint inhibitor activity and biomarkers\n# PARPi Mechanism\n## PARP proteins and NAD+ dependency\n## Poly-ADP-ribosylation (PARylation) and cellular effects","[{\"question\":\"Why are PARP inhibitors of interest in ovarian cancer?\",\"answer\":\"PARP inhibition targets DNA repair pathways. PARPi’s are particularly beneficial in BRCA-mutant and/or homologous recombination deficient (HRD) ovarian cancer, where DNA repair is already impaired.\"},{\"question\":\"What limitation motivates combination therapy with PARP inhibitors and immune checkpoint inhibitors?\",\"answer\":\"Immune checkpoint inhibitors have shown underwhelming clinical benefits in ovarian cancer, and responses have been limited for BRCA wild-type, homologous recombination proficient (HRP) cancers. This drives attempts to improve outcomes using combination approaches and related biomarker guidance.\"},{\"question\":\"Which biomarkers are mentioned as potentially relevant for ICI effectiveness?\",\"answer\":\"The text highlights programmed death ligand-1 (PD-L1), tumor mutational burden (TMB), tumor-infiltrating lymphocytes (TILs), and tumor microenvironment (TME) components as biomarkers used in other cancers to enhance ICI activity.\"}]","Review - Targeted Combination of Poly(ADP-ribose) Polymerase Inhibitors and Immune Checkpoint Inhibitors Lacking Evidence of Benefit - Focus in Ovarian Cancer | PDF",1790013496,53]